Physician profile
Alison E Cameron
NPI 1871783605
$5,468.99
in general payments reported to CMS, 2019-2025
17 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.98 · 2022: $427 · 2023: $1,310 · 2024: $1,777 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.90 | 2022-2025 | |
| Axsome Therapeutics, INC. | $736.28 | 2024-2025 | Auvelity |
| Alkermes, INC. | $663.99 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $576.99 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $551.40 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $474.17 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $441.14 | 2023-2025 | Rexulti |
| Lundbeck LLC | $288.63 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $271.04 | 2022-2025 | Austedo, Uzedy |
| Corium, LLC | $133.95 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $107.49 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $99.85 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.25 | 2022-2023 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $40.77 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $40.64 | 2024 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.04 | 2025 | Sublocade |
| Pfizer INC. | $19.46 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.